MX2023004869A - Anticuerpos contra sars-cov-2 y usos de los mismos. - Google Patents

Anticuerpos contra sars-cov-2 y usos de los mismos.

Info

Publication number
MX2023004869A
MX2023004869A MX2023004869A MX2023004869A MX2023004869A MX 2023004869 A MX2023004869 A MX 2023004869A MX 2023004869 A MX2023004869 A MX 2023004869A MX 2023004869 A MX2023004869 A MX 2023004869A MX 2023004869 A MX2023004869 A MX 2023004869A
Authority
MX
Mexico
Prior art keywords
cov
antibodies against
against sars
antibodies
sars
Prior art date
Application number
MX2023004869A
Other languages
English (en)
Spanish (es)
Inventor
Simon James Watson
Volker Germaschewski
Paul Kellam
Anne Palser
Benjamin David Grimshaw
Spela Binter
Jaroslaw Michal Szary
Margot Billaud
Robert Rowlands
Aishwarya Krishna
Huan - Chun Lin
Cheng - Yuan YANG
Li - Ying Liou
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of MX2023004869A publication Critical patent/MX2023004869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
MX2023004869A 2020-10-27 2021-10-27 Anticuerpos contra sars-cov-2 y usos de los mismos. MX2023004869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004869A true MX2023004869A (es) 2023-06-01

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004869A MX2023004869A (es) 2020-10-27 2021-10-27 Anticuerpos contra sars-cov-2 y usos de los mismos.

Country Status (12)

Country Link
US (1) US20250026813A1 (enExample)
EP (1) EP4237442A1 (enExample)
JP (1) JP2023549067A (enExample)
KR (1) KR20230113295A (enExample)
CN (1) CN117396501A (enExample)
AU (1) AU2021369450A1 (enExample)
CA (1) CA3199594A1 (enExample)
CO (1) CO2023006684A2 (enExample)
GB (1) GB202017058D0 (enExample)
IL (1) IL302244A (enExample)
MX (1) MX2023004869A (enExample)
WO (1) WO2022090353A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN121002058A (zh) * 2022-12-09 2025-11-21 艾布维兹生物公司 针对SARS-CoV-2及其变体的抗体或其片段
CN120981481A (zh) * 2023-01-10 2025-11-18 萨那生物技术股份有限公司 Cd19特异性抗体构建体以及它们的组合物
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof

Also Published As

Publication number Publication date
AU2021369450A9 (en) 2025-04-10
CN117396501A (zh) 2024-01-12
WO2022090353A1 (en) 2022-05-05
US20250026813A1 (en) 2025-01-23
EP4237442A1 (en) 2023-09-06
AU2021369450A1 (en) 2023-06-22
GB202017058D0 (en) 2020-12-09
JP2023549067A (ja) 2023-11-22
CO2023006684A2 (es) 2023-05-29
KR20230113295A (ko) 2023-07-28
IL302244A (en) 2023-06-01
CA3199594A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
WO2020160193A3 (en) Compounds and uses thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2018234793A3 (en) Antibodies
PH12023500023A1 (en) Cdk2 degraders and uses thereof
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12022550509A1 (en) Anti-cd73 antibodies
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
MY203971A (en) Anti-lag-3 antibodies and compositions
WO2018170351A8 (en) Anti-phf-tau antibodies and uses thereof
ZA202309516B (en) Anti-ccr8 antibodies
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
AU2018279184A1 (en) Anti-TrkB antibodies
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
ZA202401405B (en) Compositions and methods for anti-pacap antibodies